Learn more about TECENTRIQ® (atezolizumab), a cancer immunotherapy treatment, by clicking on the respective indication of interest:

 

HCC

TNBC

UC

Hepatocellular carcinoma1

TECENTRIQ®▼ (atezolizumab) in combination with Avastin® (bevacizumab) is indicated for the treatment of adult patients with advanced or unresectable HCC who have not received prior systemic therapy

 

Non-small cell lung cancer (NSCLC):1,2

Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.

Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.

 

Small cell lung cancer (SCLC):1

Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

 

Triple-negative breast cancer (TNBC):2

Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

 

Urothelial carcinoma (UC): 1,2

Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma:

  • after prior platinum-containing chemotherapy, or
  • who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5%

 

PAN-INDICATION resources - coming soon

References:

  1. TECENTRIQ Summary of Product Characteristics 1200mg vial. Available at https://www.medicines.org.uk/emc/product/8442/smpc
  2. TECENTRIQ Summary of Product Characteristics 840mg vial. Available at https://www.medicines.org.uk/emc/product/10697/smpc
 

M-GB-00002101
Date of preparation: November 2020